{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Allergies&page=11", "query": { "condition": "Multiple Allergies", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 386, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Allergies&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Allergies&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T05:09:39.640Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00766090", "title": "Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "GW685698X", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 190, "start_date": "2008-10", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 16, "location_summary": "Long Beach, California • Torrance, California • Cocoa, Florida + 12 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Cocoa", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00766090" }, { "nct_id": "NCT01279057", "title": "A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rhinitis, Allergic, Seasonal" ], "interventions": [ { "name": "Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)", "type": "DRUG" }, { "name": "Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandoz", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 727, "start_date": "2010-12-27", "completion_date": "2011-02-08", "has_results": true, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 7, "location_summary": "Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Austin", "state": "Texas" }, { "city": "Austin", "state": "Texas" }, { "city": "Kerrville", "state": "Texas" }, { "city": "New Braunfels", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01279057" }, { "nct_id": "NCT03431610", "title": "A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "SB414 2%", "type": "DRUG" }, { "name": "SB414 6%", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novan, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2017-11-13", "completion_date": "2018-05-11", "has_results": false, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 9, "location_summary": "Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Berlin", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03431610" }, { "nct_id": "NCT03528577", "title": "A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Zero-dose", "type": "DRUG" }, { "name": "90 mcg of PROAIR® HFA", "type": "DRUG" }, { "name": "180 mcg of 90 mcg of PROAIR® HFA", "type": "DRUG" }, { "name": "90 mcg of albuterol sulfate inhalation aerosol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 128, "start_date": "2018-09-22", "completion_date": "2019-08-03", "has_results": true, "last_update_posted_date": "2021-01-22", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 8, "location_summary": "Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Gastonia", "state": "North Carolina" }, { "city": "Edmond", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03528577" }, { "nct_id": "NCT03422822", "title": "Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Abrocitinib 100 mg", "type": "DRUG" }, { "name": "Abrocitinib 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 3166, "start_date": "2018-03-08", "completion_date": "2025-12-22", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 156, "location_summary": "Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422822" }, { "nct_id": "NCT05084963", "title": "A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "IRL201104", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolo Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2021-10-29", "completion_date": "2022-10-24", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Murrieta, California • Centennial, Colorado + 19 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05084963" }, { "nct_id": "NCT02477332", "title": "Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "QGE031", "type": "BIOLOGICAL" }, { "name": "Omalizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 382, "start_date": "2015-07-15", "completion_date": "2017-06-12", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477332" }, { "nct_id": "NCT03181009", "title": "Multi OIT to Test Immune Markers After Minimum Maintenance Dose", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Food Allergy" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Food Flour Allergens", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew Long, PharmD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 60, "start_date": "2017-07-31", "completion_date": "2019-01-30", "has_results": true, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 2, "location_summary": "Los Angeles, California • Mountain View, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03181009" }, { "nct_id": "NCT07266402", "title": "A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Inducible Urticaria", "Cold Urticaria", "Cold-Induced Urticaria", "Symptomatic Dermographism" ], "interventions": [ { "name": "Barzolvolimab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2026-01-15", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Napa", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266402" }, { "nct_id": "NCT07205081", "title": "Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Normal Volunteers", "Atopic Dermatitis (AD)", "Atopic Eczema", "Atopic Eczema/Dermatitis (Non-Specific)" ], "interventions": [ { "name": "ATTO-3712", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Attovia Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2025-10-22", "completion_date": "2026-08-13", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-23T05:09:39.640Z", "location_count": 9, "location_summary": "Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Rocklin", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07205081" } ] }